<DOC>
	<DOCNO>NCT00181688</DOCNO>
	<brief_summary>The main purpose study determine effect ( good bad ) Iressa plus anastrozole patient relapse ovarian cancer .</brief_summary>
	<brief_title>Iressa ( ZD1839 ) Plus Anastrozole ( Arimidex ) Patients With Ovarian Cancer</brief_title>
	<detailed_description>- Patients receive Iressa anastrozole orally daily treatment end . Treatment end follow occur : Unacceptable adverse effect ; bowel obstruction ; initiation systemic chemotherapy ; development new ascites pleural effusion , development co-morbid disease disease progression . - Patients give drug log record date time take pill , well symptom concomitant medication . - Patients see monthly follow test procedure ; physical examination repeat blood work . Patients remain free clinical symptom repeat abdominal/pelvic CT scan chest x-rays every 3 month basis .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<criteria>Histologic cytologic history diagnosis primary ovarian , primary peritoneal tubal carcinoma Asymptomatic ovarian cancer Evidence recurrent ovarian , peritoneal tubal carcinoma Tumor sample must positive ER and/or PR 18 year age old ECOG performance status less equal 1 Must able tolerate oral intake Known hypersensitivity Iressa excipients product Other coexist malignancy malignancy diagnose within last 5 year Concomitant use phenytoin , carbamazepine , barbiturate , rifampicin , phenobarbital St. John 's wort Treatment nonapproved investigational drug within 30 day Any unresolved chronic toxicity great CTC grad 2 previous anticancer therapy ( except alopecia ) Incomplete heal previous oncologic major surgery Serum creatinine level great CTC grade 2 Pregnant breast feeding Severe uncontrolled systemic disease Significant clinical disorder laboratory find make potentially unsafe subject participate Patients currently receive investigational antineoplastic agent , systemic chemotherapy radiation therapy treatment Patients previously treat anastrozole aromatase inhibitor Unable tolerate oral medication Clinical and/or radiographic evidence current impend bowel obstruction</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Iressa</keyword>
	<keyword>ZD1839</keyword>
	<keyword>Anastrozole</keyword>
	<keyword>Arimidex</keyword>
</DOC>